Cleveland Diagnostics has developed the IsoClear™ platform, a novel technology designed to enhance cancer diagnostics by focusing on the structural differences in proteins. This platform enables the identification of biomarkers that originate from cancer cells, thereby improving the accuracy and specificity of cancer detection. By measuring these structural changes, the IsoClear platform facilitates the development of a range of affordable blood tests, which aim to provide clearer insights into cancer diagnostics and help in making informed medical decisions.

One of the key products derived from the IsoClear platform is the IsoPSA test, which significantly improves the detection of prostate cancer compared to traditional PSA tests. IsoPSA has demonstrated a high sensitivity and specificity, reducing unnecessary prostate biopsies by up to 55%. This test not only enhances the negative predictive value of PSA testing but also streamlines the decision-making process for patients with elevated PSA levels, potentially sparing them from unnecessary procedures and costs. Overall, Cleveland Diagnostics' innovative approach aims to redefine early cancer detection and improve patient outcomes through more precise diagnostic tools.

United States

Cleveland Diagnostics is developing a breakthrough technology to discover a new class of diagnostics tests with high sensitivity and specificity for many cancers – early on, when cancer is still curable.

Cleveland Diagnostics

Company Details